COHERUS BIOSCIENCES, INC. (NASDAQ:CHRS) Files An 8-K Other Events
Item 8.01 Other Events

On May 10, 2017, Amgen Inc. (Amgen) and Amgen Manufacturing Limited filed a complaint against Coherus BioSciences, Inc. (Coherus), in the United States District Court for the District of Delaware alleging infringement by Coherus of one or more claims of Amgen’s U.S. patent no. 8,273,707.

About COHERUS BIOSCIENCES, INC. (NASDAQ:CHRS)

Coherus BioSciences, Inc. is a late-stage clinical biologics platform company. The Company is focused on the global biosimilar market. The Company operates through developing and commercializing biosimilar products segment. Its business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta), in late clinical-stage, and bevacizumab (Avastin), in preclinical-stage; Immunology (Anti-TNF) biosimilar candidates, etanercept (Enbrel) and adalimumab (Humira), which are both in late clinical-stage; Ophthalmology biosimilar candidate ranibizumab (Lucentis) in preclinical stage, and Multiple sclerosis small molecule therapeutic candidate, CHS-131 (formerly INT-131), in Phase II proof-of-concept trial. Its long-acting granulocyte colony-stimulating factor (G-CSF) product candidate, CHS-1701, is a pegfilgrastim (Neulasta) biosimilar. Its clinical-stage pipeline consists of two anti-Tumor Necrosis Factors (anti-TNFs).

COHERUS BIOSCIENCES, INC. (NASDAQ:CHRS) Recent Trading Information

COHERUS BIOSCIENCES, INC. (NASDAQ:CHRS) closed its last trading session up +0.20 at 22.35 with 677,489 shares trading hands.